Latest news for Adamant DRI (OTC:ADMG) Stock

Adamant DRI Processing and Minerals Group is a shell company.

News

Intraday Update

Markets

Movers

Trading Ideas

AAVMY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACRX

ADMG

ANGO

AOXY

ASPCF

ATRO

ATROB

AWLCF

BIOIF

BLUBF

BMMJ

BNFT

BORR

BSBR

BSET

BUDFF

CDEV

CEIX

CJPRY

CNNB

CPNFF

CRWG

CTRM

CULP

CVGI

CYBQY

DKAM

DKGR

DLRYF

DMCHY

DYLLF

ECOL

EJPRY

EMLL

ENBL

ETCC

ETFM

GEIN

GFGSF

GLYE

GNMK

GTCH

HAIPF

HNRG

IMAC

INND

ITEX

JAMN

JAPSY

KEQU

KNCAF

KOTMY

LATF

LIVE

LNTH

LONE

LPRRF

LQDT

MAHLY

MHVYF

MLMZF

MSPC

METALLIS RESOURCES INC by Metallis Resources, Inc.

MTLFF

MZDAF

NAKD

NBLX

NINOY

NMCI

NSANF

NSANY

NTGR

NZRFF

OMVKY

Stocks That Hit 52-Week Lows On Tuesday

ADAMANT DRI PRCNG &MNRLS by Adamant DRI Processing and Minerals Group

Adamant DRI Processing and Minerals Group

Lipocine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: a randomized, placebo-controlled Phase 2 trial" in the journal Hepatology and discussion at The Liver Meeting (AASLD) 2024 Editor's Cut: Clinical Study Session held on November 16, 2024. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for overt hepatic encephalopathy and sarcopenia indications. A copy of the publication can be accessed <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4304805-1&amp;h=1195872298&amp;u=https%3A%2F%2Fjournals.lww.com%2Fhep%2Fabstract%2F9900%2Foral_lpcn_1148_improves_sarcopenia_and_hepatic.1074.aspx&amp;a=here">here</a>.
The publication features the results from a Phase 2 proof-of-concept clinical trial (LPCN 1148-21-001) that evaluated LPCN 1148 in men with cirrhosis and sarcopenia awaiting liver transplantation. The trial was conducted in two stages. Stage 1 was double blind, placebo-controlled with participants randomized 1:1, to receive either oral LPCN 1148 or placebo. This was followed by Stage 2, a 28-week single-arm open label extension. The publication reports the analyses from the Stage 1 readout.
The results at 24 weeks showed that LPCN 1148 therapy resulted in a significant improvement in sarcopenia when compared with placebo. Furthermore, despite most participants already on background therapies for HE, participants receiving LPCN 1148 also experienced significantly fewer episodes of overt hepatic&nbsp;encephalopathy (OHE) compared to those on placebo. Additional beneficial effects of LPCN 1148, including improved muscle quality, hemoglobin, and patient reported symptom improvement are also covered in the manuscript.
The publication was discussed at The Liver Meeting during 'The Editors Cut: Clinical Studies' session. This session critically discusses the most notable, influential, cutting edge, game changing clinical research papers published during the past year.

Biotech

General

LPCN

Lipocine Announces The Publication And Discussion Of A Manuscript "Oral LPCN 1148 Improves Sarcopenia And Hepatic Encephalopathy In Male Patients With Cirrhosis: A Randomized, Placebo-controlled Phase 2 Trial" In The Journal Hepatology And Discussion At The Liver Meeting 2024 Editor's Cut

Actinium Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 24.49 percent increase over losses of $(0.49) per share from the same period last year.

Earnings

ATNM

Actinium Pharmaceuticals Q3 EPS $(0.37) Misses $(0.30) Estimate

ACRS

Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) with a Outperform and raises the price target from $92 to $105.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Assured Guaranty, Raises Price Target to $105

RVTY

Revvity Announces Investor Day For Nov. 21 And Updates Organizational Structure; Applied Genomics To Merge Into Life Sciences Solutions In Fiscal 2025, Streamlining Operations And Enhancing Customer Focus Across Key Markets

<a href="https://www.globenewswire.com/Tracker?data=-QW-u4gy0j6s3TaJWTrbeEe73NtGe4Tb55n18CRSdTy1J1hwkSUeWC5jkGG_zp9W2OFObQE_HpO5giP-JQxw1zhzTUXU5Uep8_RsrR9dBIs=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it had completed the purchase of 110 Bitcoin for $10 million, at an average price of $90,932 per Bitcoin.
The purchase follows the Company's announcement on November 12 of its "Bitcoin-first" strategy in which it is committing 90% or more of its current and future reserves to be held in Bitcoin, with an initial target of $120 million in Bitcoin. The $10 million of Bitcoin purchased since the announcement is the first of ongoing purchases the Company intends to make towards its target.

Genius Group Launches Bitcoin Treasury With Purchase Of 110 Bitcoin For $10M

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B

<ul>
<li>Published in the Journal of Clinical Anesthesia, results from the two-phase, 250 patient pilot study show clinicians found a majority (82%) of the alarms from the wireless and wearable Portrait Mobile monitoring solution to be informative or useful to optimize patient care in medical-surgical units.1</li>
<li>Study findings suggest that continuous monitoring helps provide critical information to clinicians, enabling them to intervene effectively before a patient deteriorates.</li>
<li>Undetected patient deterioration, particularly post-surgery, can lead to hazardous yet preventable consequences, with 30-day mortality after surgery representing the third leading cause of death globally.2</li>
</ul>
GE HealthCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) today announced the publication of data from a two-phase pilot study conducted with Cleveland Clinic in the peer-reviewed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0952818024002903%3Fvia%253Dihub&amp;esheet=54153539&amp;newsitemid=20241118649936&amp;lan=en-US&amp;anchor=Journal+of+Clinical+Anesthesia&amp;index=1&amp;md5=3882fc8ec1955dd12edab44322fe51f9">Journal of Clinical Anesthesia</a>, highlighting performance of the wireless and wearable Portrait&#x2122; Mobile monitoring solution in the post-surgical ward environment.
With published alarm rates from critical care and cardiac telemetry units that number in the hundreds per bed per day, healthcare systems may be concerned with alarm management in lower acuity settings.3,4 The results from this study highlight the potential of the wireless and wearable Portrait Mobile monitoring solution to provide meaningful alarms for clinicians and help encourage clinical intervention while minimizing alarm fatigue.1
The COSMOS (Continuous Ward Monitoring with the GE HealthCare Portrait Mobile Monitoring Solution) pilot study compares continuous monitoring with Portrait Mobile to routine intermittent vital signs assessment only. Key findings include:
<ul>
<li>In the Portrait Mobile group, there was an average of less than three alarms per patient per day.</li>
<li>Clinicians found a majority (82%) of the Portrait Mobile alarms to be informative or useful.</li>
<li>Portrait Mobile alarms informed clinical decisions, and the most common nursing intervention was theinitiation of oxygen therapy or increase in the concentration of oxygen administered to a patient. Clinicians were prompted to supplement oxygen in about 60% more patients assigned to the Portrait Mobile group compared to patients with intermittent monitoring only (49 vs. 33, respectively).
<ul>
<li>In the Portrait Mobile group, continuous monitoring and alerts led to clinical interventions that reduced vital sign abnormalities by approximately 25%.</li>
</ul>
</li>
</ul>

GEHC

GE HealthCare Announces The Publication Of Data From A Two-Phase Pilot Study Conducted With Cleveland Clinic In The Peer-Reviewed Journal Of Clinical Anesthesia, Highlighting Performance Of The Wireless And Wearable Portrait Mobile Monitoring Solution In The Post-Surgical Ward Environment

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.0500</td>
<td align="right">2.61</td>
<td align="right">1.22</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">95.1000</td>
<td align="right">0.37</td>
<td align="right">0.39</td>
<td>23.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.9100</td>
<td align="right">0.04</td>
<td align="right">0.08</td>
<td>80.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.0103</td>
<td align="right">0.05</td>
<td align="right">0.06</td>
<td>28.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.82</td>
<td align="right">-0.16</td>
<td align="right">-0.38</td>
<td>841</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.11</td>
<td align="right">-0.14</td>
<td align="right">-0.18</td>
<td>9.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">138.90</td>
<td align="right">-0.21</td>
<td align="right">-0.16</td>
<td>437</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">141.65</td>
<td align="right">-0.19</td>
<td align="right">-0.14</td>
<td>16.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">228.70</td>
<td align="right">-0.01</td>
<td align="right">-0.01</td>
<td>21.2K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For November 18, 2024

CTNM

Contineum Therapeutics Announces FDA Authorization Of Its IND Application For PIPE-791

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith upgrades MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) from Market Perform to Outperform and raises the price target from $6.5 to $9.

Upgrades

Keefe, Bruyette & Woods Upgrades MBIA to Outperform, Raises Price Target to $9

Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) today announced that Steve Rasche will step down as executive vice president and chief financial officer effective Jan. 1, 2025. He will continue to serve as a senior adviser until his retirement on April 1, 2025. &nbsp;Adam Woodard, Spire's vice president and treasurer, will succeed him as executive vice president and chief financial officer effective Jan. 1, 2025.
After joining Spire in 2009 and becoming CFO in 2013, Rasche helped drive significant growth, leading Spire to become one of the largest publicly traded natural gas companies in the country.

Management

Spire Announces Chief Financial Officer Retirement; Adam Woodard, Spire's Vice President And Treasurer, Will Succeed As Executive Vice President And Chief Financial Officer Effective Jan. 1, 2025

Benchmark analyst Mark Zgutowicz maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and raises the price target from $41 to $45.

GLBE

Benchmark Maintains Buy on Global E Online, Raises Price Target to $45

Guidance

BTBT

Bit Digital Continues To Expect To Reach $100M Run-rate Revenue Target For HPC Business By The End Of 2024

<a href="https://www.accesswire.com/943818/tharimmune-presents-positive-clinical-data-at-aasld-the-liver-meetingr-to-support-th104-for-chronic-pruritus-in-chronic-liver-disease" title="https://www.accesswire.com/943818/tharimmune-presents-positive-clinical-data-at-aasld-the-liver-meetingr-to-support-th104-for-chronic-pruritus-in-chronic-liver-disease">https://www.accesswire.com/943818/tharimmune-presents-positive-clinical-data-at-aasld-the-liver-meetingr-to-support-th104-for-chronic-pruritus-in-chronic-liver-disease</a>

THAR

Tharimmune Announces Presentation At AASLD The Liver Meeting

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

MicroStrategy Acquires 51,780 Bitcoins For $4.6B In Cash Between Nov. 11 And Nov. 17, Strengthening Its Crypto Holdings

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD
Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells and Plasmablasts, Indicative of Immune Reset
Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- &nbsp;Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. The patient, a 27-year-old African American-Asian woman diagnosed with lupus nephritis (LN) over ten years ago, received fludarabine-free conditioning followed by a single dose of FT819. The patient achieved DORIS (definition of remission in&nbsp;SLE) clinical remission and LLDAS (low lupus disease activity state) as of Month 6 follow-up. The patient continues on-study, in clinical remission, and free of all immunosuppressive therapies as of a data cutoff date of November 11, 2024. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.

FATE

Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61f3ddfca8bef8000120d89f/john-todaro">Needham analyst John Todaro</a> upgraded the rating for Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Hold to Buy and announced a $40 price target. Robinhood shares closed at $32.32 on Friday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird analyst Joel Beatty upgraded Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from Neutral to Outperform and raised the price target from $3 to $11. Amylyx Pharma shares closed at $4.76 on Friday. <a href="https://www.benzinga.com/quote/AMLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5c/gary-mobley">Loop Capital analyst Gary Mobley </a>upgraded Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) from Hold to Buy and maintained the price target of $660. Monolithic Power shares closed at $573.38 on Friday. <a href="https://www.benzinga.com/quote/MPWR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Vikram Kesavabhotla upgraded the rating for Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Neutral to Outperform and increased the price target from $70 to $90. Roku shares closed at $68.87 on Friday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital analyst Jeffrey Silber upgraded the rating for Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from Market Perform to Outperform but lowered the price target from $137 to $125. Bright Horizons Family shares closed at $104.00 on Friday. <a href="https://www.benzinga.com/quote/BFAM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18080535/image-182-1024x533.png" alt="" class="wp-image-652864" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18080535/image-182-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18080535/image-182-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18080535/image-182-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18080535/image-182.png 1233w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

BFAM

HOOD

MPWR

ROKU

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin activity and holdings, capital markets activity, and BTC yield, a key performance indicator that it recently adopted.
BTC Update
Semler Scientific announced that, during the period between November 6, 2024 and November 15, 2024, it acquired 215 bitcoins for $17.7 million in cash, at an average price of $82,502 per bitcoin, inclusive of fees and expenses.
As of November 15, 2024, Semler Scientific held an aggregate of 1,273 bitcoins, which were acquired at an aggregate purchase price of $88.7 million and an average purchase price of $69,682 per bitcoin, inclusive of fees and expenses.
ATM Update
As previously disclosed in Semler Scientific's registration statement on Form S-3 that became effective on August 13, 2024, Semler Scientific entered into a Controlled Equity Offeringsm&nbsp;Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co., pursuant to which Semler Scientific may issue and sell from time to time up to $50.0 million of its common stock in an at-the-market (ATM) offering. Since the effective date of the S-3 and as of November 15, 2024, Semler Scientific had sold an aggregate of 505,544 shares under the Sales Agreement for aggregate net proceeds (less sales commissions) of $21.5 million.&nbsp;&nbsp;
BTC Yield as a Key Performance Indicator (KPI)
From October 1, 2024 to November 15, 2024, Semler Scientific's BTC Yield was 18.9%. From July 1, 2024 (the quarter after Semler Scientific adopted its bitcoin treasury strategy) to November 15, 2024, Semler Scientific's BTC Yield was 37.3%.
Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor's understanding of Semler Scientific's decision to fund the purchase of bitcoin by issuing additional shares of its common stock.

SMLR

Semler Scientific Announces BTC And ATM Activity Raised $21.5M; Purchased Additional 215 BTC; Now Holds 1,273 BTC With BTC Yield of 37.3%

UBS analyst Joshua Spector upgrades Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) from Neutral to Buy and announces $375 price target.

UBS Upgrades Air Products & Chemicals to Buy, Announces $375 Price Target

Adamant DRI

Comments

Adamant DRI

News

Latest news for Adamant DRI (OTC:ADMG) Stock

Tuesday, February 18, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga